Investors, brokers, high-ranking delegates, big pharma and Aussie small caps will all be sharing a room at the upcoming AusBiotech Invest & Partnering 2019 event in late October.

The southern hemisphere’s biggest biotech investment event, the full-day conference will give all in attendance a rare opportunity to hear about the latest developments in the Australian and global biotech world.

Taking place on October 31 at the Melbourne Convention and Exhibition Centre, the event will feature keynote speakers, 25 biotech businesses both private and public, an anticipated 400 delegates and a wealth of enthusiastic investors.

The idea behind the event, AusBiotech says, is to demonstrate the potential of life sciences companies, which are building a wave of momentum in a low growth earnings environment.

One-to-one business partnering is also available for delegates to pre-arrange business meetings with presenting companies and delegates, and maximise their networking opportunities. Previous years have seen more than 200 investor-company meetings brokered.

Keynote presenters include Dr Niels Emmerich, Vice President of $163 billion NYSE-listed pharmaceutical company AbbVie, and Karimah Es Sabar, CEO and partner of Canadian private firm Quark Ventures.

A large range of Australian small cap biotech companies will be presenting, including Neuroscientific Biopharmaceuticals (ASX:NSB) and the resurgent Actinogen (ASX:ACW).

A link to the full program of companies presenting is available to download here:

The Australian life sciences ecosystem is stable, AusBiotech says, with strong economic and political environments supporting it, including a generous research and development tax incentive, the Clinical Trials Notification scheme, and government funds.

The sector employs more than 232,000 people across 1600+ organisations, and delivers $5 billion gross value to Australia’s economy. Australian life science companies have a proven track record of taking discoveries through the innovation process to commercialisation, hence their interest to investors.

You can register free for the event here: